The more than 38 million Americans who suffer from dry eye syndrome now have another therapy at their disposal to help relieve dry eye symptoms.
Oyster Point Pharmaceuticals announced that the FDA has approved Tyrvaya to be used to treat dry eye syndrome. The twice daily nasal spray can be used to treat mild, moderate or severe dry eye symptoms.
Tyrvaya works by utilizing a nerve pathway from within the nasal passages. Participants in the clinical trials demonstrated significant improvement in their tear film production. Tyrvaya will cost around $10 out of pocket for patients whose insurers will not cover it and will be available starting in November 2021.